Comments to: Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
作者信息
Călugăru Dan, Călugăru Mihai
机构信息
Department of Ophthalmology, University of Medicine, Cluj-Napoca - Romania.
出版信息
Eur J Ophthalmol. 2017 May 11;27(3):e107-e108. doi: 10.5301/ejo.5000949.
PMID:28315512
Abstract
摘要
相似文献
1
Comments to: Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
Eur J Ophthalmol. 2017 May 11;27(3):e107-e108. doi: 10.5301/ejo.5000949.
2
Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.在年龄相关性脉络膜新生血管中从雷珠单抗转换为阿柏西普进行抗VEGF治疗的临床经验
Eur J Ophthalmol. 2017 May 11;27(3):342-345. doi: 10.5301/ejo.5000861. Epub 2016 Oct 3.
3
Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration.在治疗新生血管性年龄相关性黄斑变性时，在雷珠单抗和阿柏西普之间转换。
Surv Ophthalmol. 2018 Sep-Oct;63(5):638-645. doi: 10.1016/j.survophthal.2018.02.004. Epub 2018 Feb 22.
4
5
Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.雷珠单抗和阿柏西普抑制血管内皮生长因子时间差异的临床相关性。
Br J Ophthalmol. 2016 Nov;100(11):1494-1498. doi: 10.1136/bjophthalmol-2015-308264. Epub 2016 Feb 17.
6
Author's reply to comments to: Clinical experience of switching anti-VEGF therapy from ranimizumab to aflibercept in age-related choroidal neovascularization.作者对《年龄相关性脉络膜新生血管中抗VEGF治疗从雷珠单抗转换为阿柏西普的临床经验》评论的回复
Eur J Ophthalmol. 2017 May 11;27(3):e109. doi: 10.5301/ejo.5000931.
7
Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.雷珠单抗和阿柏西普用于治疗湿性年龄相关性黄斑变性。
Expert Opin Biol Ther. 2015;15(9):1349-58. doi: 10.1517/14712598.2015.1057565. Epub 2015 Jun 16.
8
PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.贝伐单抗、雷珠单抗和阿柏西普在体外极化视网膜色素上皮层中的通透性及抗血管内皮生长因子作用
Retina. 2017 Jan;37(1):179-190. doi: 10.1097/IAE.0000000000001117.
9
Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab.阿柏西普对雷珠单抗和贝伐单抗治疗无效患者视力及黄斑中心厚度的短期影响
Wien Klin Wochenschr. 2017 May;129(9-10):351-357. doi: 10.1007/s00508-016-1055-0. Epub 2016 Aug 22.
10
Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.转换为玻璃体内注射阿柏西普后息肉状脉络膜血管病变患者的黄斑中心凹下脉络膜厚度
Jpn J Ophthalmol. 2016 Jan;60(1):35-41. doi: 10.1007/s10384-015-0411-3. Epub 2015 Sep 9.
引用本文的文献
1
Romanian ophthalmologists in the renowned ophthalmic journals worldwide.罗马尼亚眼科医生发表于全球知名眼科期刊上的文章。 （原英文表述不太完整准确，推测完整意思应该是类似这样，若按照字面翻译是：罗马尼亚眼科医生在全球著名眼科期刊里）
Rom J Ophthalmol. 2018 Oct-Dec;62(4):260-269.
2
Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy.光动力疗法联合玻璃体内注射阿柏西普及球周注射曲安奈德治疗阿柏西普耐药性息肉状脉络膜血管病变的疗效
Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):233-235. doi: 10.1007/s00417-017-3797-4. Epub 2017 Sep 6.
Zotero 插件